NewsRelease

JournalArticle Cites HemogloBind™ in Pig DevelopmentStudy

MONMOUTHJUNCTION, NJ, July9, 2019-- Biotech Support Group reports on an article describing thesimplicity and efficiency of their hemoglobin depletion technologyfor improving ELISA analysis from hemolyzed pig serum.  

The citationis:

Craig,J. R., et al. "Acomparison of the anatomical and gastrointestinal functionaldevelopment between gilt and sow progeny around birth andweaning." Journalof animal science (2019).

Giltprogeny (GP) often have restricted growth performance and healthstatus in comparison to sow progeny (SP) from birth. To betterunderstand underlying mechanisms, the study aimed to comparedifferences in growth and development between GP and SP in the first24 h after birth and in the peri-weaning period. Becauseserumsamples were quite hemolysed after collection and processing, itbecame necessary to use HemogloBind™ to allow for better detectionof IgG by ELISA.The article states “As per the manufacturer’s instructions, 250μL of Hemoglobind was added to 250 μL of hemolyzed serum, vortexedfor 30 s before mixing via inversion for 10 min, and then centrifugedat 6,000 g for2 min at 4°C. Purified serum was then aspirated and assessed induplicate for IgG concentration … using a commercial ELISA kit(Bethyl Laboratories, Montgomery TX, USA).” Theauthors conclude theirfindings suggest that the early development of GP may be delayedcompared to SP, and that a number of the anatomical differencesbetween GP and SP that exist after birth are also present at weaning.

“Thelarge amount of hemoglobin can often interfere with ELISAmeasurements. This article demonstrates that HemogloBind™ canreduce the interference associated with large concentrations ofhemoglobin, without compromising the recovery and analysis of theunderlying proteome, in this case IgG. As our technology does notrely on immuno-affinity, the product has the versatility to work onany species, as the authors demonstrate here on pigs” states SwapanRoy, Ph.D., President and Founder of Biotech Support Group.

Formore information on HemogloBind™, visit:

http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

Forinformation on all Hemoglobin Removal products: visit:

https://www.biotechsupportgroup.com/Articles.asp?ID=452

AboutBiotech Support Group LLC

Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com 

BusinessDevelopment Contact:

MattKuruc 732-274-2866, [email protected]